Pharmacological approach for the reduction of inflammatory and prothrombotic hyperactive state in COVID-19 positive patients by acting on complement cascade.
Hum Immunol
; 82(4): 264-269, 2021 Apr.
Article
in English
| MEDLINE | ID: covidwho-1039363
ABSTRACT
The novel Coronavirus SARS-CoV-2 is the viral pathogen responsible for the ongoing global pandemic, COVID-19 (Coronavirus disease 2019). To date, the data recorded indicate 1.62 Mln deaths and 72.8 Mln people infected (WHO situation report Dec 2020). On December 27, the first anti-COVID-19 vaccinations started in Europe. There are no direct antivirals against SARS-CoV-2. Understanding the pathophysiological and inflammatory/immunological processes of SARS-CoV-2 infection is essential to identify new drug therapies. In the most severe COVID-19 cases, an unregulated immunological/inflammatory system results in organ injury that can be fatal to the host in some cases. Pharmacologic approaches to normalize the unregulated inflammatory/immunologic response is an important therapeutic solution. Evidence associates a non-regulation of the "complement system" as one of the causes of generalized inflammation causing multi-organ dysfunction. Serum levels of a complement cascade mediator, factor "C5a", have been found in high concentrations in the blood of COVID-19 patients with severe disease. In this article we discuss the correlation between complement system and COVID-19 infection and pharmacological solutions directed to regulate.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Complement C3a
/
Complement C5a
/
Complement Activation
/
Complement Inactivating Agents
/
COVID-19 Drug Treatment
Topics:
Vaccines
Limits:
Humans
Language:
English
Journal:
Hum Immunol
Year:
2021
Document Type:
Article
Affiliation country:
J.humimm.2021.01.007
Similar
MEDLINE
...
LILACS
LIS